panobinostat

CINC424A2X01B Rollover Protocol

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Panobinostat Biological Correlates Study

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma